Literature DB >> 25424937

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Mayrel Labrada1, Isabel Pablos, Francesca Prete, Giselle Hevia, Marilyn Clavell, Federica Benvenuti, Luis E Fernández.   

Abstract

While the NGcGM3/VSSP vaccine, a preparation consisting in very small sized proteoliposomes (VSSP) obtained by the incorporation of the NGcGM3 ganglioside into the outer membrane protein (OMP) complex of Neisseria meningitides, is currently studied in late stage clinical trials in breast cancer and melanoma patients, mechanisms involved in the vaccine's antitumor effect are insufficiently understood. Here we have addressed the role of adaptive and innate immune cells in mediating the protective effect of the vaccine. To this aim we selected the 3LL-D122 Lewis lung spontaneous metastasis model. Unexpectedly, inoculation of the vaccine in tumor bearing C57BL/6 mice, either by subcutaneous (sc) or intraperitoneal (ip) routes, induced similar anti-metastatic effect. Regardless the T-independent nature of NGcGM3 ganglioside as antigen, the antimetastatic effect of NGcGM3/VSSP is dependent on CD4(+) T cells. In a further step we found that the vaccine was able to promote the increase, maturation, and cytokine secretion of conventional DCs and the maturation of Bone Marrow-derived plasmacytoid DCs. In line with this result the in vivo IFNα serum level in ip vaccinated mice increased as soon as 2h after treatment. On the other hand the infiltration of NK1.1(+)CD3(-) and NK1.1(+)CD3(+) cells in lungs of vaccinated mice was significantly increased, compared with the presence of these cells in control animal lungs. In the same way NGcGM3/VSSP mobilized acquired immunity effector cells into the lungs of vaccinated tumor bearing mice. Finally and not less noteworthy, leukocyte infiltration in lungs of tumor bearing mice correlates with vaccine induced inhibition of lung metastization.

Entities:  

Keywords:  NGcGM3; VSSP; cancer immunotherapy; ganglioside; leukocyte infiltration

Mesh:

Substances:

Year:  2014        PMID: 25424937      PMCID: PMC4896779          DOI: 10.4161/hv.29161

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  48 in total

1.  IFN-beta-mediated up-regulation of CD1d in bacteria-infected APCs.

Authors:  Gayatri Raghuraman; Yanbiao Geng; Chyung-Ru Wang
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Authors:  Maciej Kmieciak; Debasmita Basu; Kyle K Payne; Amir Toor; Adly Yacoub; Xiang-Yang Wang; Lisa Smith; Harry D Bear; Masoud H Manjili
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

3.  Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.

Authors:  Julia Steitz; Jürgen Brück; Julia Lenz; Steffi Büchs; Thomas Tüting
Journal:  J Invest Dermatol       Date:  2005-01       Impact factor: 8.551

4.  A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.

Authors:  A Carr; A Mullet; Z Mazorra; A M Vázquez; M Alfonso; C Mesa; E Rengifo; R Pérez; L E Fernández
Journal:  Hybridoma       Date:  2000-06

5.  Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma.

Authors:  G Ritter; E Boosfeld; R Adluri; M Calves; H F Oettgen; L J Old; P Livingston
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

Review 6.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

Review 7.  NGcGM3/VSSP vaccine as treatment for melanoma patients.

Authors:  Kirenia Pérez; Marta Osorio; Julio Hernández; Adriana Carr; Luis Enrique Fernández
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

8.  Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.

Authors:  Georgios Chamilos; Russell E Lewis; Jianhua Hu; Lianchun Xiao; Tomasz Zal; Michel Gilliet; Georg Halder; Dimitrios P Kontoyiannis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-26       Impact factor: 11.205

Review 9.  Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin.

Authors:  F Helling; P O Livingston
Journal:  Mol Chem Neuropathol       Date:  1994 Feb-Apr

10.  Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.

Authors:  Adriana Carr; Edmundo Rodríguez; María del Carmen Arango; Rolando Camacho; Marta Osorio; Mariano Gabri; Guido Carrillo; Zolidina Valdés; Yanín Bebelagua; Rolando Pérez; Luis Enrique Fernández
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more
  2 in total

1.  Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.

Authors:  Addys González Palomo; Armando López Medinilla; Valeria Segatori; María Del Carmen Barroso; Rances Blanco; Mariano R Gabri; Adriana Carr Pérez; Kalet León Monzón
Journal:  Oncotarget       Date:  2018-05-08

2.  Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.

Authors:  Addys González Palomo; Rancés Blanco Santana; Xiomara Escobar Pérez; Damián Blanco Santana; Mariano Rolando Gabri; Kalet León Monzon; Adriana Carr Pérez
Journal:  Clin Exp Metastasis       Date:  2016-07-23       Impact factor: 5.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.